Risk of cancer development in relation to oral contraception

References

• Hatcher R A, Trussel J, Stewart F, et al. Contraception Technology, 16th revised edition. Irvington Publishers, New York 1994
   Google Scholar
• Szamatowicz M. Antykoncepcja hormonalna u progu XXI wieku. Wiad Poł Gin 2000; 1: 45–56
   Google Scholar
• Service R F. New role for the estrogen in cancer?. Science 1998; 279: 1631–1633
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713–1727
   PubMed Web of Science ®Google Scholar
• Hankinson S E, Colditz G A, Manson J E, et al. A prospective study of oral contraceptive use and risk of breast cancer. Cancer Causes Control 1997; 8: 65–72
   PubMed Web of Science ®Google Scholar
• Marchbanks P A, McDonald J A, Wilson H G, et al. Oral contraceptives and the risk of breast cancer. New Engl J Med 2002; 346: 2025–2032
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 2001; 358: 1389–1399
   PubMed Web of Science ®Google Scholar
• Grabick D M, Harmann L C, Cerhan J R, et al. Risk of breast cancer with oral contraceptive use in women with a family cancer. J Am Med Assoc 2000; 284: 1791–1798
   PubMed Web of Science ®Google Scholar
• Heimdal K, Skovlund E, Moller P. Oral contraceptives and risk of familial breast cancer. Cancer Detect Prev 2002; 26: 23–27
   PubMedGoogle Scholar
• Marchbanks P A, McDonald J A, Wilson H G, et al. Oral contraceptives and the risk of breast cancer. New Engl J Med 2002; 346: 2025–2032
   PubMed Web of Science ®Google Scholar
• Beral V, Hermon C, Kay C, et al. Mortality associated with oral contraceptive use: 25 year follow up cohort of 46 000 women from Royal College of General Practitioners' oral contraception study. Br Med J 1999; 318: 96–100
   PubMed Web of Science ®Google Scholar
• Verheul H AM, Coellingh-Bennink H JT. Effects of estrogens and hormone replacement therapy on breast cancer risk and on efficacy of breast cancer therapies. Maturitas 2000; 36: 1–17
   PubMed Web of Science ®Google Scholar
• Kenemans P, Van der Mooren J. The breast and post-menopausal hormone therapy: the risk in perspective. Gynaecol Forum 2004; 9: 15–17
   Google Scholar
• Speroff L. Spojrzenie z dystansu na raport WHI dotyczący raka sutka. Gin po Dypl 2004; 6: 55–59
   Google Scholar
• Pujol P, This P, Norizunia M, et al. Are the hereditary forms of BRCA 1 and BRCA 2 breast cancer sensitive to estrogens?. Bull Cancer 2004; 91: 583–591
   PubMed Web of Science ®Google Scholar
• Narod S A, Dube M P, Klijn J, et al. Oral contraceptive use increased the risk of breast cancer in BRCA1, but not BRCA2, mutations carriers. J Natl Cancer Inst 2002; 94: 1173–1179
   PubMedGoogle Scholar
• Milne R L, Knight J A, John E M, et al. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 2005; 14: 350–356
   PubMed Web of Science ®Google Scholar
• Polskie Towarzystwo Ginekologiczne. Rekomendacje dotyczące ryzyka dziedzicznie uwarunkowanego zachorowania na raka gruczołu sutkowego i jajnika. Gin po Dypl 2004; 6: 53–54
   Google Scholar
• Scott A, Glasier A. Routine breast and pelvic examinations before prescription of hormonal contraception. IPPF Med Bull 2003; 37: 1–2
   Google Scholar
• Westhof C L. Breast cancer risk: perception versus reality. Contraception 1999; 59(Suppl 1)25–8S
   PubMedGoogle Scholar
• Bucholc M, Łepecka-Klusek C, Pilewska A, Kanadys K. Ryzyko zachorowania na raka piersi w opinii kobiet. Gin Pol 2001; 72: 1460–1464
   PubMedGoogle Scholar
• Smith J, Green J, Berrington de Gonzalez A, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003; 361: 1159–1167
   PubMed Web of Science ®Google Scholar
• Miller K, Blumenthal P, Blanchard K. Oral contraceptives and cervical cancer: critique of a recent review. Contraception 2004; 69: 347–351
   PubMed Web of Science ®Google Scholar
• de Villiers E M. Relationship between steroid hormone contraceptives and HPV, cervical intraepithelial neoplasia and cervical carcinoma. Int J Cancer 2003; 103: 705–708
   PubMed Web of Science ®Google Scholar
• Moreno V, Bosch F X, Munoz N, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 2002; 359: 1085–1092
   PubMed Web of Science ®Google Scholar
• Crosignani P G, Vegetti W, Bianchedi D. Hormonal contraception and ovarian pathology. Eur J Contracept Reprod Health Care 1997; 2: 207–211
   PubMedGoogle Scholar
• Ness R B, Grisso J A, Klapper J, et al. Oral contraceptives, other methods of contraception, and reduced risk for ovarian cancer. Epidemiology 2001; 12: 307–312
   PubMed Web of Science ®Google Scholar
• Bosetti C, Negri E, Trichopoulos D, et al. Long-term effects of oral contraceptives on ovarian cancer risk. Int J Cancer 2002; 102: 262–265
   PubMed Web of Science ®Google Scholar
• Narod S A, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. New Engl J Med 1998; 339: 424–428
   PubMed Web of Science ®Google Scholar
• Modan B, Hartge P, Hirsch-Yechezkel G, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. New Engl J Med 2001; 345: 235–240
   PubMed Web of Science ®Google Scholar
• Greer J B, Modugno T, Glen O, et al. Short term oral contraceptives use and the risk of epithelial ovarian cancer. Am J Epidemiol 2005; 162: 66–72
   PubMed Web of Science ®Google Scholar
• Schlesselmman J J, Collins J A. The influence of steroids on gynecologic cancers. Estrogens and progestogens in clinical practice, I S Fraser, R PS Jansen, R A Lobo, M I Whitehead. Churchill Livingstone, London 1999; 831–864
   Google Scholar
• Fernandez E, La Vecchia C, Balducci A, et al. Oral contraceptives and colorectal cancer risk: a meta-analysis. Br J Cancer 2001; 81: 722–727
   Google Scholar
• Hannaford P, Elliot A. Use of exogenous hormones by women and colorectal cancer: evidence from the Royal College of General Practitioners' Oral Contraception Study. Contraception 2005; 71: 95–98
   PubMed Web of Science ®Google Scholar
• Tajada M, Nerin J, Ruiz M M, et al. Liver adenoma and focal nodular hyperplasia associated with oral contraceptives. Eur J Contracept Reprod Health Care 2001; 6: 227–230
   PubMed Web of Science ®Google Scholar
• Heinemann L AJ, DoMinh T, Guggenmoos-Holzmann I, et al. Oral contraceptives and liver cancer. Contraception 1997; 56: 275–284
   PubMed Web of Science ®Google Scholar
• Feskanich D, Hunter D J, Willett W C, et al. Oral contraceptive use and risk of melanoma in premenopausal women. Br J Cancer 1999; 81: 918–923
   PubMed Web of Science ®Google Scholar
• Pfahlberg A, Hassan K, Wille L, et al. Systematic review of case-control studies: Oral contraceptives show no effect on melanoma risk. Public Health Rev 1997; 25: 309–315
   PubMedGoogle Scholar
• Victory R, Souza C D, Diamond M P, et al. Reduced cancer risks in oral contraceptive users: Results from the Women's Health Initiative. Fertil Steril 2004; 82(Suppl 2)S104–S105
   Google Scholar